Seizert Capital Partners LLC Invests $3.90 Million in LivaNova PLC (NASDAQ:LIVN)

Key Points

• Seizert Capital Partners LLC acquired 99,184 shares of LivaNova PLC, valued at approximately $3.9 million, representing a 0.18% ownership stake.
• Multiple institutional investors have significantly increased their positions in LivaNova, with UMB Bank n.a. raising their stake by 340.5% during the first quarter.
• LivaNova's stock performance includes a 1-year low of $32.48 and a high of $57.35, and it currently holds an average price target of $59.29 from analysts.

Seizert Capital Partners LLC acquired a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 99,184 shares of the company's stock, valued at approximately $3,896,000. Seizert Capital Partners LLC owned 0.18% of LivaNova as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Freestone Grove Partners LP bought a new stake in shares of LivaNova in the fourth quarter valued at about $23,102,000. The Manufacturers Life Insurance Company boosted its position in LivaNova by 163.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock valued at $25,303,000 after buying an additional 339,139 shares during the last quarter. AQR Capital Management LLC boosted its position in LivaNova by 79.3% in the 4th quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock worth $34,214,000 after purchasing an additional 328,313 shares in the last quarter. Vanguard Group Inc. boosted its position in LivaNova by 12.7% in the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock worth $108,823,000 after purchasing an additional 265,291 shares in the last quarter. Finally, Capital Research Global Investors lifted its position in shares of LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock valued at $74,690,000 after buying an additional 258,730 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on LIVN shares. Needham & Company LLC reiterated a "buy" rating and set a $64.00 price target on shares of LivaNova in a report on Tuesday, May 13th. Robert W. Baird boosted their price objective on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a report on Tuesday, May 20th. Barclays dropped their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. Finally, Wall Street Zen downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, LivaNova has a consensus rating of "Buy" and a consensus target price of $59.29.

LivaNova Price Performance

Shares of NASDAQ LIVN traded down $1.06 during mid-day trading on Friday, reaching $41.13. The company had a trading volume of 800,401 shares, compared to its average volume of 602,376. The stock has a market cap of $2.24 billion, a PE ratio of -10.06 and a beta of 0.92. The company has a 50-day moving average price of $44.64 and a two-hundred day moving average price of $42.86. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $57.35.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.